Michael Ryskin
Stock Analyst at B of A Securities
(1.39)
# 3,424
Out of 4,893 analysts
37
Total ratings
47.83%
Success rate
-2.9%
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $68 → $70 | $58.41 | +19.84% | 6 | Jun 25, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $535 → $475 | $540.64 | -12.14% | 3 | Apr 21, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Buy | $9 → $8 | $2.76 | +189.86% | 3 | Mar 3, 2025 | |
| ALGN Align Technology | Maintains: Underperform | $200 → $206 | $200.48 | +2.75% | 6 | Dec 13, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $51.04 | -21.63% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $5.96 | +59.40% | 1 | Jun 25, 2024 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $11.47 | +109.24% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $13.57 | +76.86% | 2 | Jul 31, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $158.27 | +13.73% | 7 | Nov 4, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $5.59 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $21.69 | +139.80% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $2.83 | +253.36% | 2 | Nov 10, 2021 |
Tempus AI
Jun 25, 2025
Maintains: Neutral
Price Target: $68 → $70
Current: $58.41
Upside: +19.84%
IDEXX Laboratories
Apr 21, 2025
Maintains: Neutral
Price Target: $535 → $475
Current: $540.64
Upside: -12.14%
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.76
Upside: +189.86%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200 → $206
Current: $200.48
Upside: +2.75%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $51.04
Upside: -21.63%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $5.96
Upside: +59.40%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $11.47
Upside: +109.24%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $13.57
Upside: +76.86%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $158.27
Upside: +13.73%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.59
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $21.69
Upside: +139.80%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $2.83
Upside: +253.36%